CRIS Current Research Information System

RICCI, ANGELA DALIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.186
EU - Europa 912
AS - Asia 552
AF - Africa 57
SA - Sud America 4
OC - Oceania 2
Totale 2.713
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.184
SG - Singapore 243
SE - Svezia 202
IT - Italia 196
CN - Cina 180
DE - Germania 132
GB - Regno Unito 104
IE - Irlanda 94
CH - Svizzera 85
IN - India 64
FI - Finlandia 39
JO - Giordania 24
TG - Togo 22
CI - Costa d'Avorio 20
ID - Indonesia 16
RU - Federazione Russa 13
NG - Nigeria 11
BG - Bulgaria 10
NL - Olanda 8
FR - Francia 7
TR - Turchia 6
AT - Austria 5
PL - Polonia 5
PS - Palestinian Territory 5
JP - Giappone 4
BE - Belgio 3
CL - Cile 3
HK - Hong Kong 3
CA - Canada 2
CD - Congo 2
ES - Italia 2
KR - Corea 2
NZ - Nuova Zelanda 2
RS - Serbia 2
UA - Ucraina 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
BR - Brasile 1
DK - Danimarca 1
LV - Lettonia 1
PH - Filippine 1
RO - Romania 1
SA - Arabia Saudita 1
SC - Seychelles 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 2.713
Salva come PNG Salva come JPEG
Città #
Singapore 222
Chandler 204
Princeton 97
Dublin 92
Santa Clara 91
Bern 83
Southend 81
Fairfield 73
Boardman 67
Ashburn 59
Bologna 58
Helsinki 34
Houston 31
New York 26
Seattle 26
Berlin 25
Florence 25
Amman 24
Lomé 22
Beijing 21
Abidjan 20
Redmond 17
Cambridge 16
Jakarta 14
San Diego 14
Woodbridge 14
Wilmington 13
Abeokuta 11
Turin 11
Frankfurt am Main 10
Shanghai 10
Sofia 10
Bühl 8
Los Angeles 8
Milan 8
Boydton 7
Des Moines 7
Guangzhou 7
Ann Arbor 6
Hyderabad 6
Olalla 6
Rome 6
Halhul 5
Harbin 5
Lappeenranta 5
London 5
Medford 5
Siena 5
Xi'an 5
Zhengzhou 5
City of Westminster 4
Fontanelice 4
Fulham 4
Austin 3
Brescia 3
Brussels 3
Chiyoda-ku 3
Council Bluffs 3
Forlì 3
Hong Kong 3
Istanbul 3
Jinan 3
Nanjing 3
Nuremberg 3
Qingdao 3
Quanzhou 3
Shenzhen 3
Vienna 3
Warsaw 3
Amsterdam 2
Auckland 2
Chicago 2
Dongguan 2
Foshan 2
Fuzhou 2
Genoa 2
Kinshasa 2
Langfang 2
Moscow 2
Napoli 2
North Kuta 2
Parma 2
Pieve di Cento 2
Redwood City 2
Salamanca 2
San Francisco 2
Santiago 2
Springfield 2
Taicang 2
Taizhou 2
Tianjin 2
Vidnoye 2
Weifang 2
Westminster 2
Wuhan 2
Wuxi 2
Xingtai 2
Aldie 1
Alexandria 1
Ankara 1
Totale 1.749
Salva come PNG Salva come JPEG
Nome #
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 163
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 124
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis 91
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 83
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 78
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 75
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 71
Landscape and future perspectives of immunotherapy in neuroendocrine neoplasia 70
Experimental HER2- targeted therapies for biliary tract cancer 69
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 69
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 68
Hacking pancreatic cancer: Present and future of personalized medicine 68
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 65
The functioning side of the pancreas: a review on insulinomas 64
Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma 63
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 61
Tumor-associated macrophages and inflammatory microenvironment in gastric cancer: Novel translational implications 59
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 59
Novel HER2-directed treatments in advanced gastric carcinoma: Another paradigm shift? 55
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 54
Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer 53
Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data 50
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer 50
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 49
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study 48
Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art 46
Circulating tumor DNA in biliary tract cancer: Current evidence and future perspectives 46
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 45
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue 44
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives 44
Nivolumab: an investigational agent for the treatment of biliary tract cancer 44
Bone targeting agents in patients with metastatic prostate cancer: State of the art 43
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 43
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma 43
Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives 39
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 38
Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look 38
First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges 33
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future 33
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects 30
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): A new Pandora's box? 30
Pd‐l1, tmb, msi, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer 29
Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies 28
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? 27
Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? 27
Systemic adjuvant treatment in hepatocellular carcinoma: Tempted to do something rather than nothing 27
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 25
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis 25
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue 25
Recent advances of immunotherapy for biliary tract cancer 25
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? 24
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials 22
Atezolizumab in advanced hepatocellular carcinoma: Good things come to those who wait 22
Toward personalized therapy for cholangiocarcinoma: new insights and challenges 22
Regarding “HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer” 22
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma 21
In Regard to “A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)” 21
DNA damage response alterations in gastric cancer: Knocking down a new wall 20
Radiofrequency ablation for intrahepatic cholangiocarcinoma: a tool upon the path of integrative modalities? 18
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis 11
Immune-based combinations for advanced hepatocellular carcinoma: Shaping the direction of first-line therapy 7
Totale 2.846
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.545
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.545
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202035 0 0 0 0 0 0 0 12 8 7 5 3
2020/2021118 17 2 3 4 5 5 8 12 23 13 4 22
2021/2022596 13 4 8 13 18 5 12 42 168 52 172 89
2022/20231.074 84 115 43 102 77 117 36 62 179 56 77 126
2023/2024309 58 41 20 22 25 50 20 20 6 27 11 9
2024/2025714 61 190 151 102 142 61 7 0 0 0 0 0
Totale 2.846